Nonsurgical management benefits nearly all patients with AS, and surgery is reserved for a highly selected group. In the recent past, there have been promising developments in the medical management of AS. Because AS has a high prevalence in the population (range 0.1–2%), affected patients can present to neurosurgeons with neurosurgical disorders unrelated to AS. To provide comprehensive care to patients with AS requiring neurosurgical care, it is important for all neurosurgeons to be well versed in nonsurgical management of this entity. In this article we give an overview of the current evidence-based nonsurgical management of AS. Relevant pathophysiology of the disease is reviewed to underscore the targets of the various pharmacological agents.

Pathology and Site of Action of Pharmacological Agents

Ankylosing spondylitis is a chronic, immune-mediated inflammatory disease that is associated with inflammation in the sacroiliac joints, the axial skeleton, entheses, peripheral joints, uvea, and other structures. The initial pathological changes are initiated by macrophage infiltration that leads to synovitis and enthesitis. The macrophages are later replaced by lymphocytes, leading to release of a large number of inflammatory mediators, most significant of which are TNF, vascular endothelial growth factor, and IL-1. These inflammatory mediators lead to bone erosion, pannus, and granulation tissue formation. The eroded bone heals by osseous ankylosis. To prevent these pathological changes, a number of steps can be targeted by various pharmacological agents (Fig. 1). Briefly, the nonsurgical treatment modalities can be classified into 7 groups.
improve function to a varying extent: 1) physiotherapy and education; 2) simple analgesics; 3) NSAIDs and coxibs; 4) local and systemic corticosteroids; 5) radiotherapy; 6) DMARDs; 7) biological treatments (TNF and IL-1 inhibitors).

**Nonsurgical Management**

**Nonpharmacological Treatment**

*Physical Therapy.* Physical therapy in the form of home exercises has been shown to improve function (Level Ib evidence) in the short term as reported by Dagfinrud et al. in a Cochrane database review. However, it is still not clear which treatment protocol (group physical therapy, home exercises, or a combination) should be recommended in the management of AS. Balneotherapy (treatment by bathing) has been shown in a randomized clinical trial to have a supplementary effect on improvement in disease activity and functional parameters in patients with AS immediately after the treatment period. No study, however, has been conducted to determine the long-term benefits of these interventions. Although spa therapy is popular, there are no good studies supporting this intervention.

*Patient Education.* At the 12-month follow-up examination Basler and Rehfisch found that cognitive–behavioral therapy had reduced patients’ pain intensity, anxiety, and psychophysiological symptoms. Although pain reduction was statistically significant, it did not exceed 14% in the pain diary. The more important aspect of the treatment appeared to be emotional stabilization and increased feelings of well-being. Group education has also been shown to be useful.
Nonsurgical management of ankylosing spondylitis

Pharmacological Treatment

**Simple Analgesics and Opioids.** Analgesics such as paracetamol can reduce pain and thus improve a patient’s functional capacity. However, there is insufficient evidence in the literature to support the aforementioned assertion outright. The only available study was performed by Pal,17 in which the author found that simple analgesic agents were less effective than NSAIDs for controlling pain in AS. Opioids can be used as alternatives to NSAIDs or as supplementary analgesics.12

**Nonsteroidal Antiinflammatory Drugs and Coxibs.** Nonsteroidal antiinflammatory drugs continue to be the first-line treatment in AS.25 After diagnosis, symptomatic patients are started on a course of NSAID therapy, with close monitoring of the clinical response. There is Level Ib evidence that NSAIDs improve spinal pain and function in the short term.27 Although conventionally these groups of drugs have been considered symptom-modifying agents, there is now evidence that they also are disease-modifying agents.24 The inhibition of radiographic progression by continuous intake of NSAIDs can be explained by their inhibition of prostaglandins; however, this proposition warrants further study. Several in vitro studies and animal investigations have shown impaired bone healing in the presence of NSAIDs. The steps associated with bone fusion include an inflammatory response, chondrogenesis, and finally bone formation. Through inhibition of COX and subsequently prostaglandins, NSAIDs may inhibit new bone formation.19 This inhibition is clinically used to prevent postoperative ossification. There may be differences related to the degree of COX-1 and COX-2 inhibition by the various NSAIDs. Coxibs are a group of NSAIDs with selective COX-2 inhibition. An inducible enzyme, COX-2 converts arachidonic acid to prostaglandin E2, a modulator of bone metabolism. A cytoprotective enzyme, COX-1 is present in the gastric mucosa, kidneys, and heart. Nonsteroidal antiinflammatory drugs cause increased gastrointestinal bleeding, which is dose dependent and can be reduced with gastroprotective agents such as misoprostol, double doses of H2 blocker, and proton pump inhibitors. Cardiovascular toxicity with coxibs and NSAIDs is now well established, which has led to withdrawal of certain NSAIDs from the market.27

**Local and Systemic Corticosteroids.** There is Level Ib evidence supporting the pain-improving efficacy of intra- and periarticular steroid injections into the sacroiliac joints.15 There is no evidence of any role for intraarticular steroid injections into other regions of the spine.27 There is also no evidence of any role for the systemic use of steroids in AS.27

**Disease-Modifying Antirheumatic Drugs**

**Sulfasalazine.** The best investigated DMARD for the treatment of AS is sulfasalazine. Chen and Liu performed a metaanalysis of the role of sulfasalazine in AS and concluded that it exhibited some benefit in reducing the erythrocyte sedimentation rate and easing spinal stiffness in all patients with AS but that it showed no evidence of benefit in physical function, pain, spinal mobility, enthesitis, or patient and physician global assessment. The authors reported that there were more withdrawals for side effects (relative risk 1.47, 95% confidence interval 1.01–2.13) in the sulfasalazine group than in the placebo group, although severe side effects were rare. They also concluded that patients in whom the disease was seen at an early stage—with higher erythrocyte sedimentation rate (or active disease) and with peripheral arthritis—might benefit from sulfasalazine treatment. There is also evidence that sulfasalazine prevents attacks of AS-associated uveitis.27 Hence, at the moment there is only limited evidence that sulfasalazine has an overall efficacy in AS, with a possible effect in early and peripheral arthritis.

**Methotrexate.** Methotrexate is an antimetabolite that prevents the conversion of bihydrofolic acid to tetrahydrofolic acid. Although the authors of a few small open studies involving methotrexate have reported a potential effect in AS, a metaanalysis performed by Chen and Liu failed to reveal that it had any role. No placebo-controlled studies have been performed to date.

Aside from case reports there are no studies involving patients with AS receiving other DMARDs that are effective in the treatment of rheumatoid arthritis such as gold, azathioprine, cyclosporine A, or leflunomide.27

**Biological Treatments**

**Tumor Necrosis Factor Inhibitors.** Tumor necrosis factor is a proinflammatory cytokine that has been labeled as a

---

**TABLE 1**

**Summary of ASAS/EULAR proposals for the management of AS**

| 1) | treatment of AS tailored according to symptoms, signs & expectation of patient |
| 2) | disease monitoring should include clinical parameters, laboratory tests, & imaging. |
| 3) | optimal management requires a combination of nonpharmacological & pharmacological treatments |
| 4) | nonpharmacological treatment should include patient education & regular exercise; individual & group physical therapy should be considered; patient associations & self-help groups may be useful |
| 5) | NSAIDs are recommended as first-line drug treatment in cases of pain & stiffness |
| 6) | analgesics, such as acetaminophen & opioids, might be considered for pain control when NSAIDs are insufficient, contraindicated, &/or poorly tolerated |
| 7) | corticosteroid injections directed to the local site of musculoskeletal inflammation may be considered; use of systemic corticosteroids for axial disease not supported by evidence |
| 8) | no evidence of efficacy of DMARDs, including sulfasalazine & methotrexate, for the treatment of axial disease; sulfasalazine may be considered in patients w/ peripheral arthritis |
| 9) | anti-TNF treatment should be given to patients w/ persistently high disease activity despite conventional treatments, according to ASAS recommendations |
| 10) | total-hip arthroplasty & spinal op should be considered in patients w/ refractory pain or disability |

---

Unauthenticated | Downloaded 06/16/22 10:00 PM UTC
“master regulator” of the immune response. This cytokine is produced primarily by macrophages and activated lymphocytes; production increases in response to inflammation, infection, or injury and results in the upregulated expression of a multitude of cytokines, including IL-1 and IL-6, which stimulate bone resorption and proteoglycan breakdown. Elevated levels of TNF mRNA and protein are found in biopsy specimens of the sacroiliac joints obtained in patients with AS. In addition, mice that express a truncated form of TNF develop an inflammatory polyarthritis resembling AS, which can be resolved with TNF-blocking therapy.

Three anti-TNF agents have been studied and 2 of these agents are approved by the FDA for the treatment of AS: etanercept, infliximab, and adalimumab.

Infliximab. Infliximab is a monoclonal chimeric human anti-TNF antibody that binds with high affinity to TNF. It is administered by intravenous infusion of 5 mg/kg body weight at baseline (0 weeks), 2 weeks, and 6 weeks and then every 6 weeks. It has shown to be clinically and radiologically effective and has been approved by the FDA.

Etanercept. Etanercept is a dimeric fusion protein of the TNF receptor linked to the Fc portion of human immunoglobulin G1. It is a recombinant p75 receptor fusion 75-kD TNF protein that acts competitively to inhibit the cell surface receptor binding of TNF. Etanercept is administered by subcutaneous injection at a dose of 25 mg twice weekly. It has been shown to be clinically and radiologically effective and has been approved by the FDA.

Adalimumab. Adalimumab is a monoclonal, fully human anti-TNF antibody that binds with high affinity to TNF. It is approved for the treatment of active rheumatoid arthritis in the US. It is given by subcutaneous injection at a dose of 40 mg every 2 weeks or weekly. It has been shown to be clinically and radiologically effective but has not yet been approved by the FDA.

**Initiation of Anti–TNF Therapy**

The indication for the initiation of anti–TNF therapy is failure of standard treatments. Before anti–TNF therapy can be initiated, however, disease activity should score at least 4 on the BASDAI (score range 0–10), with a physician’s global assessment score of at least 2 (mild disease) on the Lickert Scale. Patients must have failed to respond to treatment involving the use of 2 NSAIDs during a 3-month period (due to intolerance or lack of efficacy). If patients have peripheral arthritis or enthesitis, a DMARD such as sulfasalazine or methotrexate must also have failed to resolve symptoms. If these criteria are met, patients should be treated with etanercept (25 mg twice weekly or 50 mg once weekly) or infliximab (5 mg/kg body weight, intravenously infused at baseline, 2 weeks, 6 weeks, and then 6 weeks thereafter). Before starting anti–TNF treatment, patients must be screened for the presence of latent tuberculosis in accordance with the standard recommendations. A patient’s response to treatment is evaluated at 6 weeks and 12 weeks and is defined as an improvement of at least 50% in BASDAI score or an absolute change of 2 cm on a 0–10 visual analog scale, as well as a physical global assessment change of at least 1 Lickert unit.

**Effects on Disease Progression.** There are convincing data to show that anti-TNF therapy significantly reduces clinically and radiologically documented disease. This sustained response has been observed during nearly 2 years of etanercept therapy. Improvements in magnetic resonance imaging–based scores were persistently observed at 24 weeks. In several studies TNF inhibitors have also been shown to improve bone mineral density. Not only were TNF blockers associated with improvements in both clinical and magnetic resonance imaging scores, but these agents have also shown to improve quality of life.

**Safety.** Some of the most common adverse events are reactions to infusion, which can range from nausea, headaches, pruritis, and dizziness to hypotension, shortness of breath, and chest pain. This treatment has been associated with increased risk of infection, both common upper respiratory tract infections and opportunistic infections—in particular, tuberculosis. These patients also had higher rates of extrapulmonary tuberculosis and a higher mortality rate than individuals with tuberculosis who had not received anti–TNF therapy.

Screening for Mycobacterium tuberculosis has been shown to decrease the incidence of tuberculosis disease associated with TNF blockers and is now a standard prerequisite for anti–TNF therapy. Other serious opportunistic infections in patients who received anti–TNF therapy include histoplasmosis, coccidiomycosis, and blastomycosis. Demyelinating disease, lupuslike syndromes, and worsening of preexistent congestive heart failure have also been reported in case series, although precise incidences are not known.

**Other Treatments of AS**

Investigators have evaluated anakinra, an IL-1 inhibitor approved for the treatment of rheumatoid arthritis, in the treatment of AS. Conflicting reports are available on the efficacy of anakinra in the management of AS. Hence, larger clinical trials are required for drawing any conclusions about its efficacy.

**Recommendations of Combined ASAS/EULAR Groups.** The combined ASAS/EULAR task forces have proposed 10 recommendations for the management of AS (Table 1). These recommendations form the cornerstone of AS management. As it is for any other disease, the treatment of AS should be tailored according to the symptoms, signs, and expectations of the patient. The disease monitoring of patients should include history, clinical features, laboratory test results, and imaging findings. Some of the scoring systems used frequently in AS include the following: ASAS core sets, BASDAI, BAS Functional Index, BAS Metabolism Index, 36-Item Short Form Health Survey, and the Lickert Scale. The frequency of monitoring should be tailored to the individual based on symptoms, severity, and drug therapy. A combination of nonpharmacological and pharmacological treatments, including education and physical therapy, has been shown to produce the best clinical outcome. Tumor necrosis factor inhibitor therapy should be initiated according to ASAS recommendations. Hip replacement and spinal surgery have to be considered in patients with refractory pain and/or disability.

**Socioeconomics/Cost Effectiveness.** Despite the high costs, the clinical benefits and improvements in quality of life in
Nonsurgical management of ankylosing spondylitis

patients with AS receiving infliximab could result in lower disease-associated costs than does standard care, which translates to a short-term cost of ~ $70,000 US (per quality-adjusted life year gained). Furthermore, the daily productivity of patients with active disease, which was substantially associated with functional impairment and disease activity, could greatly improve with infliximab, and this was associated with reduced workday loss in employed patients. In a metaanalysis of the cost effectiveness of anti-TNFα therapy, however, McLeod et al. found that none of the 3 agents was cost-effective in the short term. Thus, larger clinical trials are required to prove convincingly the cost effectiveness of anti–TNFα therapy.

Conclusions

Physical therapy and education are useful for all patients diagnosed with AS. If symptomatic, patients receive either a nonselective NSAID or a selective COX-2 inhibitor. The role of NSAIDs as disease-modifying agents in the treatment of AS is being better understood. The central role of TNF in the pathogenesis of AS is now known, and the advent of biological treatment in the form of anti–TNF factors has revolutionized the medical management of AS. These agents are used in patients with axial disease who remain symptomatic despite receiving adequate doses of NSAIDs.

References


Address correspondence to: Fernando Vale, M.D., Department of Neurological Surgery, Seventh Floor, 2A Columbia Drive, University of South Florida, Tampa, Florida 33606. email: fvale@health.usf.edu.